NEUWAY Pharma is developing an entirely novel class of biotherapeutics built around its proprietary Engineered Protein Capsules (EnPC®), which can cross the blood-brain barrier and deliver transformative neuropharmaceuticals for the treatment of disorders of the central nervous system (CNS).
The company aims to be the partner of choice for developers of mRNA drug candidates and other drug modalities who need to overcome the current hurdles of delivering these into the brain and CNS tissue.
Operating as a drug developer and a delivery expert, NEUWAY will demonstrate and exploit the value of its technology through its internal rare disease pipeline for indications with a high unmet medical need as well as partnered programs.
October 30 - November 1, 2023,
TIDES Europe, Oligonucleotide & Peptide Therapeutics, Amsterdam, NL
EKKEHARD LEBERER, PHD
Scientific Advisor at NEUWAY Pharma & Life Sciences Consultant, ELBIOCON